{"id":47126,"date":"2023-04-19T16:39:56","date_gmt":"2023-04-19T11:09:56","guid":{"rendered":"http:\/\/finservwealth.com\/mankind-pharma-ipo-shares-trade-with-single-digit-premium-in-grey-market\/"},"modified":"2023-04-19T16:39:56","modified_gmt":"2023-04-19T11:09:56","slug":"mankind-pharma-ipo-shares-trade-with-single-digit-premium-in-grey-market","status":"publish","type":"post","link":"https:\/\/finservwealth.com\/hi\/mankind-pharma-ipo-shares-trade-with-single-digit-premium-in-grey-market\/","title":{"rendered":"Mankind Pharma IPO shares trade with single-digit premium in grey market"},"content":{"rendered":"<p> Mankind Pharma is focused largely on the domestic market, which contributed to 97.60 percent to its revenue from operations for FY22.<\/p><div id=\"finse-802055976\" class=\"finse-content finse-entity-placement\"><script async src=\"\/\/pagead2.googlesyndication.com\/pagead\/js\/adsbygoogle.js?client=ca-pub-9118214110898834\" crossorigin=\"anonymous\"><\/script><ins class=\"adsbygoogle\" style=\"display:block;\" data-ad-client=\"ca-pub-9118214110898834\" \ndata-ad-slot=\"\" \ndata-ad-format=\"auto\"><\/ins>\n<script> \n(adsbygoogle = window.adsbygoogle || []).push({}); \n<\/script>\n<\/div>\n<p><a href=\"https:\/\/www.moneycontrol.com\/news\/ipo-news\/mankind-pharma-ipo-shares-tradesingle-digit-premiumgrey-market_16964281.html\" target=\"_blank\" class=\"feedzy-rss-link-icon\" rel=\"noopener\">Read More<\/a><\/p>\n<p>\u200b\u00a0Mankind Pharma is focused largely on the domestic market, which contributed to 97.60 percent to its revenue from operations for FY22. Mankind Pharma is focused largely on the domestic market, which contributed to 97.60 percent to its revenue from operations for FY22.\u00a0\u00a0Moneycontrol Latest News\u00a0<a href=\"https:\/\/www.moneycontrol.com\/news\/ipo-news\/mankind-pharma-ipo-shares-tradesingle-digit-premiumgrey-market_16964281.html\" target=\"_blank\" class=\"feedzy-rss-link-icon\" rel=\"noopener\">Read More<\/a>\u00a0\u00a0<\/p>","protected":false},"excerpt":{"rendered":"<p><!-- wp:html --><\/p>\n<p> Mankind Pharma is focused largely on the domestic market, which contributed to 97.60 percent to its revenue from operations for FY22.<\/p>\n<p><a href=\"https:\/\/www.moneycontrol.com\/news\/ipo-news\/mankind-pharma-ipo-shares-tradesingle-digit-premiumgrey-market_16964281.html\" target=\"_blank\" class=\"feedzy-rss-link-icon\" rel=\"noopener\">Read More<\/a><\/p>\n<p>\u200b\u00a0Mankind Pharma is focused largely on the domestic market, which contributed to 97.60 percent to its revenue from operations for FY22. Mankind Pharma is focused largely on the domestic market, which contributed to 97.60 percent to its revenue from operations for FY22.\u00a0\u00a0Moneycontrol Latest News\u00a0<a href=\"https:\/\/www.moneycontrol.com\/news\/ipo-news\/mankind-pharma-ipo-shares-tradesingle-digit-premiumgrey-market_16964281.html\" target=\"_blank\" class=\"feedzy-rss-link-icon\" rel=\"noopener\">Read More<\/a>\u00a0\u00a0<\/p>\n<p><!-- \/wp:html --> Mankind Pharma is focused largely on the domestic market, which contributed to 97.60 percent to its revenue from operations for FY22.<\/p>","protected":false},"author":0,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"content-type":"","_monsterinsights_skip_tracking":false,"neve_meta_sidebar":"","neve_meta_container":"","neve_meta_enable_content_width":"","neve_meta_content_width":0,"neve_meta_title_alignment":"","neve_meta_author_avatar":"","neve_post_elements_order":"","neve_meta_disable_header":"","neve_meta_disable_footer":"","neve_meta_disable_title":"","_themeisle_gutenberg_block_has_review":false,"footnotes":""},"categories":[70],"tags":[],"class_list":["post-47126","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-latest-news"],"jetpack_featured_media_url":"https:\/\/www.moneycontrol.com\/news_image_files\/2022\/200x200\/I\/IPO-2_200.jpg","_links":{"self":[{"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/posts\/47126","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/comments?post=47126"}],"version-history":[{"count":0,"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/posts\/47126\/revisions"}],"wp:attachment":[{"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/media?parent=47126"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/categories?post=47126"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/tags?post=47126"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}